Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a Phase 2 clinical study titled ‘A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer.’ The study aims to assess the safety and efficacy of telisotuzumab adizutecan in combination with other drugs for treating metastatic colorectal cancer (mCRC), a prevalent cancer worldwide.
The study tests telisotuzumab adizutecan, an investigational drug, alongside established treatments like FOLFOX, bevacizumab, and panitumumab. These combinations aim to improve outcomes for mCRC patients by evaluating adverse events and changes in disease activity.
The study follows an interventional design with randomized allocation and a parallel intervention model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused.
The study began on April 24, 2025, with an estimated duration of six years. The latest update was submitted on August 5, 2025, indicating ongoing recruitment and progress.
This study could significantly impact AbbVie’s market position by potentially introducing a new treatment for mCRC, influencing investor sentiment positively. It also positions AbbVie competitively within the oncology sector, where advancements are crucial.
The study is ongoing, with further details available on the ClinicalTrials portal.